The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy

Hongfei Ji; Qijia Xuan; Caichuan Yan; Tao Liu; Abiyasi Nanding; Qingyuan Zhang

doi:10.18632/oncotarget.8993

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy

Hongfei Ji, Qijia Xuan, Caichuan Yan, Tao Liu, Abiyasi Nanding and Qingyuan Zhang _

PDF | HTML | How to cite

Oncotarget. 2016; 7:34881-34889. https://doi.org/10.18632/oncotarget.8993

Metrics: PDF 1440 views | HTML 1689 views | ?

Abstract

Hongfei Ji1,3,*, Qijia Xuan2,*, Caichuan Yan1,3, Tao Liu2, Abiyasi Nanding4, Qingyuan Zhang1,2,3

1Department of Cancer Molecular and Biology, Cancer Institute, Harbin Medical University, Harbin, China

2Department of Medical Oncology, Tumor Hospital of Harbin Medical University, Harbin, China

3Department of Cancer Molecular and Biology, Heilongjiang Academy of Medical Sciences, Harbin, China

4Department of Pathology, Tumor Hospital of Harbin Medical University, Harbin, China

*These authors have contributed equally to this work

Correspondence to:

Qingyuan Zhang, e-mail: [email protected]

Keywords: breast cancer, lymphocyte-to-monocyte ratio, 5-fluorouracil, prognostic factor

Received: December 03, 2015 Accepted: April 11, 2016 Published: April 26, 2016

ABSTRACT

Several reports have suggested that peripheral blood-based parameters are associated with host immunity response, which is an essential component of the pathogenesis and progression of cancer. The purpose of the present study was to identify the prognostic significance of various peripheral blood-based biomarkers and to determine the optimal cut-off value suitable for luminal breast cancer patients. We found that lymphocyte-to-monocyte ratio (LMR) was significant prognostic predictors. And the patients with a CEF regimen and LMR ratio ≥ 5.2 gained a good prognosis. This study suggested that the LMR could be regarded as an independent prognostic factor in luminal breast cancer patients. The elevated LMR level also had enhanced 5-fluorouracil sensitivity in luminal breast cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8993

Publication Alerts

Research Papers:

The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy

Abstract